PIRS - יחס חוב להיוון בספרים Pieris Pharmaceuticals Inc

The business liquidity of Pieris Pharmaceuticals (PIRS) relies on the success of Anticalin proteins and partner payments. The financing structure, specifically debt-to-book capitalization on the general GURU.Markets platform chart, demonstrates capital stability, where 0.09 serves as the current parameter value. This metric correlates with strict compliance with FDA medical regulations and an expansion strategy within the respiratory and oncology pathology segments.

This ratio measures the proportion of borrowed funds relative to equity, determining the business's degree of debt load. For Pieris Pharmaceuticals (PIRS), this balance is critical, as asset value is supported by Anticalin platform patents and licensing revenues. By analyzing financial dependency levels based on balance sheet capital, an investor can track leverage dynamics. An upward trend signals liquidity risk, while a consistently low figure confirms the fundamental stability of the model.